Finance

Lists
Why is LMRI up 3.34%?
Dive Deeper
LMRI:NASDAQ
Lumexa Imaging Holdings Inc
$10.21
+3.34%
(+0.33) 1D
$10.19
-0.20% (-0.020)
After hours
Closed: Sep 25, 4:00:01 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for LMRI...
Open
$10.25
High
$10.27
Low
$9.86
Mkt. cap
980.93M
Avg. vol.
444.39K
Volume
441.20K
52-wk high
$19.45
52-wk low
$6.45
EPS
-$0.25
Shares outstanding
96.08M
No. of employees
4K
Open
$10.25
High
$10.27
Low
$9.86
Mkt. cap
980.93M
Avg. vol.
444.39K
Volume
441.20K
52-wk high
$19.45
52-wk low
$6.45
EPS
-$0.25
Shares outstanding
96.08M
No. of employees
4K
News stories
From web sources and news partners
About Lumexa Imaging Holdings Inc
CEO-
Employees4.2K
Founded2018
Headquarters-
SectorHealth care provider
Websitelumexaimaging.com
Analyst ratings
Based on 6 analysts giving stock ratings to LMRI in the past 3 months
Strong buy
Buy
6
Hold
0
Sell
0
12-month forecast
Based on 6 Wall Street analysts offering 12 month price targets for LMRI in the last 3 months.
Highest
Current $10.21
$19.00 (+86.09%)
Average
$16.80 (+64.54%)
Lowest
$13.00 (+27.33%)
Analyst
Recommendation
Action
Price target
Projected
Date
Matthew Gillmor CFA
KeyBanc
Buy
Initiated
$18.00
+76.3%
09/25/2026
Andrew Mok CFA
Barclays
Buy
Maintained
$13.00
+27.3%
08/28/2026
Stephen Baxter
Wells Fargo
Buy
Maintained
$19.00
+86.1%
08/14/2026
Unknown Analyst
Deutsche Bank
Buy
Maintained
$16.00
+56.7%
08/13/2026
Ryan Daniels
William Blair
Buy
Reiterated
-
-
08/12/2026
Benjamin Rossi
J.P. Morgan
Buy
Maintained
$18.00
+76.3%
08/10/2026
John Ransom
Raymond James
Buy
Reiterated
$17.00
+66.5%
06/18/2026
Last report
Aug 12, 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
$0.20 / $0.14
+38.89%beat
Revenue / Est. (USD)
264.16M / 263.16M
+0.38%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Dec 2025
Mar 2026
Jun 2026
Revenue
251.40M
267.73M
252.54M
264.16M
Cost of goods sold
211.76M
225.62M
217.66M
225.28M
Cost of revenue
211.76M
225.62M
217.66M
225.28M
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13.49M
25.24M
16.09M
20.34M
Operating expense
22.76M
37.64M
26.01M
30.43M
Total operating expenses
234.53M
263.26M
243.67M
255.71M
Operating income
16.87M
4.48M
8.87M
8.45M
Other non operating income
-
-
-
-
EBT including unusual items
-2.42M
-25.26M
3.08M
5.76M
EBT excluding unusual items
3.30M
-1.24M
7.56M
10.85M
Income tax expense
4.81M
3.43M
1.36M
3.02M
Effective tax rate
-198.97%
-13.59%
44.27%
52.38%
Other operating expenses
-
-
-
-
Net income
-7.23M
-28.69M
1.72M
2.74M
Net profit margin
-2.87%
-10.72%
0.68%
1.04%
Earnings per share
-
0.01
0.07
0.20
Interest and investment income
-
-
-
-
Interest expense
-30.10M
-28.02M
-16.33M
-16.22M
Net interest expenses
-30.10M
-28.02M
-16.33M
-16.22M
Depreciation and amortization charges
9.28M
12.40M
9.92M
10.08M
EBITDA
26.15M
16.87M
18.79M
18.53M
Gain or loss from assets sale
16.00K
491.00K
137.00K
-24.00K
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps